Actively Recruiting
Targeting the Gut to Improve Seizure Control in CDKL5 Deficiency Disorder (CDD)
Led by University of Milan · Updated on 2024-06-07
20
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
Sponsors
U
University of Milan
Lead Sponsor
F
Fondazione Telethon
Collaborating Sponsor
AI-Summary
What this Trial Is About
Standard anti-seizure medications have limited efficacy in seizure control in cyclin-dependent kinase-like 5 deficiency disorder (CDD). The study will investigate whether targeting the gut-microbiota-brain axis in CDD patients can alleviate seizures and ameliorate other comorbidities.
CONDITIONS
Official Title
Targeting the Gut to Improve Seizure Control in CDKL5 Deficiency Disorder (CDD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of CDD with confirmed CDKL5 pathogenic variant
- Drug-resistant seizures
- Participation of a caregiver ensured
- Willingness to sign informed consent
You will not qualify if you...
- Organic gastrointestinal disorders such as food allergies or celiac disease
- Special diets
- Percutaneous endoscopic gastrostomy tube
- Use of antibiotics or probiotics in the previous month
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Milan
Milan, Italy
Actively Recruiting
Research Team
A
Aglaia Vignoli, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here